(3). This report presents information on new cancer cases and deaths for 2012. The number and rate of cancer cases and deaths are stratified by the primary cancer sites as reported for 2012; information is provided by demographic characteristic (e.g., sex, age, race, and ethnicity) and primary cancer site (68 selected sites among men and 72 selected sites among women). Age-adjusted cancer incidence and death rates are shown by primary site and year for the period 1999-2012. Ageadjusted cancer incidence and death rates for the most common sites are shown by race, sex, and ethnicity for 2012, the most recent year for which incidence data are available. Maps of the United States display age-adjusted cancer incidence and death rates, presented by quartiles, for 2012. Time trends in ageadjusted cancer incidence and death rates during 1999-2012 are shown by race, sex, and ethnicity for all sites combined, colorectal, lung and bronchus, prostate, and female breast.
Background
Cancer comprises a diverse mix of diseases occurring in every part of the body and is a leading cause of death in the United States (4) . More than half of cancer cases could be prevented (5) . Surveillance of cancer incidence and mortality can help public health officials target areas for control efforts (6) and track progress toward meeting the national health objectives set forth in Healthy People 2020 (7) . Cancer is a reportable disease in every state and thus all hospitals, physicians' offices, pathology laboratories, and other medical facilities are required to submit data on all reportable cancer diagnoses to a central cancer registry at the state or territorial level. A cancer registry is a database that contains individual records of all reportable cancer cases in a defined population and includes patient demographics, tumor characteristics (e.g., cancer site and pathology), and information about the notifying health provider or facility. In 1992, Congress established NPCR by enacting the Cancer Registries Amendment Act (Public Law 102-515) (8) . Administered by CDC, NPCR collects data on the occurrence of cancer and the type, extent, and location of the cancer. Before NPCR was established, 10 states had no registry, and most states with registries lacked the resources and state legislation needed to gather complete data (9) . Presently, NPCR supports central cancer registries in 45 states, the District of Columbia (DC), Puerto Rico, and the U.S. Pacific Island Jurisdictions. NPCR data represent 96% of the overall U.S. population. Together, NPCR and NCI's SEER Program collect data for the entire U.S. population. Cancer control planners and others can identify variations in cancer rates by population subgroups and monitor trends over time to guide the planning and evaluation of cancer prevention and control programs and allocation of health resources.
Data Sources
Data about cancer incidence and mortality in the Summary of Notifiable Noninfectious Conditions and Disease Outbreaks come from the official federal statistics on cancer, the U.S. Cancer Statistics (USCS) dataset (1) . The USCS dataset includes cancer incidence data from NPCR registries in 45 states and DC (cancer incidence data from Puerto Rico and the U.S. Pacific Island Jurisdictions were not available for this analysis) and from SEER program registries in the remaining five states (Connecticut, Hawaii, Iowa, New Mexico, and Utah) and cancer mortality data from NVSS.
Incidence Data
The primary source of data on cancer incidence is medical records. Staff at health care facilities abstract data from patients' medical records, enter it into the facility's own cancer registry if it has one, and then send the data to the regional or state registry. Both NPCR and SEER registries collect data using uniform data items and codes as documented by the North American Association of Central Cancer Registries (NAACCR). This uniformity ensures that data items collected by the two federal programs are comparable (10, 11) . Information on primary site and histology is coded according to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) and categorized according to the revised SEER recodes dated January 27, 2003, which define standard groupings of primary cancer sites (http://seer.cancer. gov/siterecode) (12) . Beginning with 2010 diagnoses, cases were first classified by anatomic site using ICD-O-3; cases with hematopoetic histologies were further classified by using the 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (13) . Data from the NPCR registries provided in this report were reported to CDC as of November 30, 2014. Data from SEER registries were reported to NCI as of November 1, 2014 .
NPCR and SEER cancer registries consider as reportable all incident cases with a behavior code of 2 (in situ, noninvasive) or 3 (malignant, primary site only) in ICD-O-3. Exceptions include in situ cancer of the cervix and all basal and squamous cell carcinomas of the skin, except for those on the skin of the genital organs (12) . Beginning with 2001 diagnoses, several cancers that are coded as malignant in ICD-O-3 were not coded as malignant in ICD-O-2 (10) . Additional information is provided in the USCS technical notes (http://www.cdc.gov/ cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#namedd est=IncidenceDataSources).
Mortality Data
Cancer mortality statistics are based on information from all death certificates filed in the 50 states and DC and processed by NVSS at NCHS (14) . The cancer mortality data were compiled in accordance with World Health Organization regulations, which specify that member nations classify and code causes of death in accordance with the current revision of the International Classification of Diseases (ICD) (15) . For consistency with the data on cancer incidence, the cancer sites in mortality data were grouped according to the revised SEER recodes dated January 27, 2003 (available at http://seer.cancer. gov/codrecode). Data for a specific calendar year are based on records of deaths that occurred during that calendar year and received by a particular date; for example, mortality data for 2012 are based on records of deaths that occurred during 2012 and were received as of June 30, 2014. Additional information is provided in the USCS technical notes (http://www.cdc.gov/ cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#namedd est=MortalityDataSources).
Population Estimates
Population denominators are race-specific, ethnicity-specific, and sex-specific county population estimates from the U.S. Census, modified by SEER and aggregated to the state and national level. Additional details about population data are available at http://seer.cancer.gov/popdata/index.html.
Interpreting Data Incidence Data
Each year, state cancer registries submit cancer cases for a new diagnosis year and an updated version of the previous years' cancer cases to CDC or NCI. Therefore, each year, when USCS data are published, updates to the previous year's data are published, using the most recent data submission and the most recent population data. Users of cancer incidence data published by federal agencies should be mindful of the data submission dates for all data used in their analyses.
Mortality Data
Cancer mortality statistics in USCS are influenced by the accuracy of information on the death certificate. Unlike incidence data, mortality data for a calendar year are considered complete when submitted and so are not updated after the aggregate data file is released. Mortality data for the entire United States refer only to deaths that occurred within the United States; data for geographic areas are provided by the decedent's place of residence.
Race and Ethnicity Data
For cancer incidence, race and ethnicity data are abstracted from medical records and grouped into categories (11) . When cancer mortality is reported, race and ethnic origin are recorded separately on the death certificate by the funeral director as
Methods for Identifying Cancer
Medical facilities such as hospitals, doctors' offices, and pathology laboratories send information about cancer cases to their cancer registry. Most information comes from hospitals, where highly trained cancer registrars transfer the information from the patient's medical record to the registry's computer software using standardized codes. The data are then sent to the central cancer registry. Every year the central cancer registries electronically submit incidence, demographic, and clinical data to NPCR or SEER.
Population Coverage
The population coverage for incidence data varies by diagnosis year. Population coverage might be affected by the suppression of state incidence data, if a state did not meet the publication criteria or did not submit data. In addition, state incidence data might be suppressed if <16 cases were reported or if the state requested that the data be suppressed. Additional information is provided by the USCS technical notes (http:// www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes. pdf#nameddest=CensusRegionPubCriteria). Mortality data from malignant neoplasms (i.e., cancers) as recorded in the NVSS from the 50 states and DC are available in USCS, and thus 100% of the U.S. population is covered each year. However, state death data might be suppressed if <16 deaths were reported.
Suppression of Rates and Counts
When the numbers of cases or deaths used to compute rates are small, those rates tend to have poor reliability. Therefore, in an effort to discourage misinterpretation or use of rates or counts that are unstable because case or death counts are small, incidence and death rates and counts of <16 are not shown in tables and figures. The use of a threshold value for suppressing cells helps protect the confidentiality of patients by reducing or eliminating the risk for disclosure of their identity. Additional information is provided in the USCS technical notes (http:// www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes. pdf#nameddest=Suppression).
Publication Criteria
Cancer incidence data that appear in this report are derived from state cancer registries that have high-quality cancer incidence data for individual (e.g., 2012) and combined (e.g., 1999-2012) years as demonstrated by meeting all of the following criteria on data quality for all cancer sites combined:
• case ascertainment is ≥90% (margin of error +5%) complete, • ≤5% of cases are ascertained solely on the basis of a death certificate, • ≤3% of cases are missing information on sex, • ≤3% of cases are missing information on age, • ≤5% of cases are missing information on race, and • ≥97% of the registry's records passed a set of single-field and inter-field computerized edits that test the validity and logic of data components. Additional information about USCS is available at http://www.cdc.gov/uscs.
Time Trends in Incidence and Death Rates
On the basis of data from registries meeting data quality criteria during 1999-2012, cancer incidence rates declined from 484 cancer cases per 100,000 population in 1999 to 434 cases in 2012 (Table 15) Figure 4 ) and by cancer site, sex, and ethnicity ( Figure 5 ). During 1999-2012, cancer death rates declined from 201 deaths per 100,000 persons in 1999 to 166 deaths in 2012; during the same period, death rates declined for each of the four most common cancers (Table 16 ). Time trends in cancer death rates are presented by cancer site, sex, and race ( Figure 6 ) and by cancer site, sex, and ethnicity ( Figure 7) . National cancer surveillance data help public health officials track progress toward achieving the national cancer objectives set forth in Healthy People 2020 (20) . For the national cancer burden to be reduced and Healthy People 2020 targets to be met, behavioral and environmental factors that increase cancer risk must be reduced, and high-quality screening services, timely follow-up, and evidence-based treatments must be available and accessible to all persons. Several effective primary and secondary prevention measures, such as vaccination against infectious agents that cause cancer (i.e., hepatitis B virus and human papillomavirus), help with smoking cessation, and cancer screening, when effectively implemented and sustained, could reduce the number of new cancer cases and prevent many cancer-related deaths (21) . Evidence-based interventions can be implemented at both the individual level and the population level to reduce cancer risk factors, promote healthy living, and encourage cancer screening (5).
* Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups -Census P25-1130). For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ). † Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except urinary bladder. Urinary bladder cancer includes invasive and in situ. § Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (covering approximately 99% of the U.S. population).
Registry-specific data quality information is available at http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria. Caution should be used when comparing incidence and death rates because of potential differences in population coverage. . For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ). † Rates are not presented for persons of unknown or other race. Data for specified racial populations other than white and black should be interpreted with caution. For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=IntRaceEthnicityData). § Data are from the National Vital Statistics System (NVSS). Data for death rates cover 100% of the U.S. population. Caution should be used when comparing incidence and death rates because of potential differences in population coverage. * Rates are the number of deaths per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups -Census P25-1130). For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ). † Data for specified ethnic populations should be interpreted with caution. For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/ pdf/uscs-2012-technical-notes.pdf#nameddest=IntRaceEthnicityData). § Data are from the National Vital Statistics System (NVSS). Data for death rates cover 100% of the U.S. population. Caution should be used when comparing incidence and death rates because of potential differences in population coverage. Abbreviation: NOS = not otherwise specified. * Rates are the number of cases per 100,000 persons. For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technicalnotes.pdf ). † Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except urinary bladder. Urinary bladder cancer includes invasive and in situ. § Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (covering approximately 99% of the U.S. population).
Registry-specific data quality information is available at http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria. ¶ Counts and rates are suppressed if <16 cases were reported in a specific category. Some counts and rates are suppressed as complementary cell suppression. Abbreviations: NA = not applicable; NOS = not otherwise specified. * Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups -Census P25-1130). For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ). † Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except urinary bladder. Urinary bladder cancer includes invasive and in situ. § Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (covering approximately 99% of the U.S. population).
Registry-specific data quality information is available at http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria. Abbreviations: AI/AN = American Indian/Alaska Native; A/PI = Asian/Pacific Islander; NOS = not otherwise specified. * Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups -Census P25-1130). For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ). † Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except urinary bladder. Urinary bladder cancer includes invasive and in situ. § Rates are not presented for persons of unknown or other race, therefore categories do not sum to total. Data for specified racial populations other than white and black should be interpreted with caution. For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes. pdf#nameddest=IntRaceEthnicityData). ¶ Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (covering approximately 99% of the U.S. population).
Registry-specific data quality information is available at http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria. ** Counts and rates are suppressed if <16 cases were reported. Abbreviations: AI/AN = American Indian/Alaska Native; A/PI = Asian/Pacific Islander; NOS = not otherwise specified. * Rates are the number of deaths per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups -Census P25-1130). For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ). † Data for specified racial populations other than white and black should be interpreted with caution. For more information, see USCS technical notes (http://www. cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=IntRaceEthnicityData). § Data are from the National Vital Statistics System (NVSS). ¶ Counts and rates are suppressed if <16 deaths were reported. Abbreviation: NOS = not otherwise specified. * Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups -Census P25-1130). For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ). † Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except urinary bladder. Urinary bladder cancer includes invasive and in situ. § Rates and counts are not presented for persons of unknown ethnicity, therefore categories do not sum to total. Data for specified ethnic populations should be interpreted with caution. For more information, see USCS technical notes http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest= IntRaceEthnicityData). ¶ Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (covering approximately 99% of the U.S. population).
Registry-specific data quality information is available at http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria. ** Counts and rates are suppressed if <16 cases were reported. Some counts and rates are suppressed as complementary cell suppression. Abbreviation: NOS = not otherwise specified. * Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups -Census P25-1130). For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ). † Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except urinary bladder. Urinary bladder cancer includes invasive and in situ. § Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined for all years, 1999-2012 (covering approximately 92% of the U.S. population). See registry-specific data quality information for all years, 1999-2012 (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf#nameddest=RegistriesPubCriteria). Caution should be used when comparing incidence and death rates because of potential differences in population coverage. Peritoneum, omentum, and mesentery Abbreviation: NOS = not otherwise specified. * Rates are the number of deaths per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups -Census P25-1130). For more information, see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2012-technical-notes.pdf ). † Data are from the National Vital Statistics System (NVSS). Data for deaths cover 100% of the U.S. population. Caution should be used when comparing incidence and death rates because of potential differences in population coverage.
